Investment, Funding & Disinvestments

The therapy, known as NRTX-1001, uses pluripotent stem cells engineered to regulate brain activity and repair damaged neural networks.

Under the agreement, Stereotaxis will pay USD20 million upfront, with up to an additional USD25 million tied to milestone-based payments.

For Daiichi Sankyo, divesting this business allows the company to concentrate resources on its innovative medicines division, where it has emerged as a leader in antibody-drug conjugate (ADC) technology.

CrossBridge Bio plans to submit an Investigational New Drug (IND) application for CBB-120, positioning the candidate for clinical development.

The collaboration leverages JW Pharmaceutical’s established research and development capabilities to accelerate the drug’s entry into South Korea’s growing metabolic disease sector.

The company receives USD10 million in near-term milestones and stands to earn up to USD 705 million additional milestone payments upon reaching key development and regulatory benchmarks.

The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.

Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners co-led the financing initiative.

The government has set a bold target: by 2030, Egypt will manufacture 140 million human vaccine doses per year.

This shift applies to all three Merck vaccines distributed by Zhifei: Gardasil, the rotavirus vaccine RotaTeq, and the pneumococcal vaccine Pneumovax 23.